Hormonal Contraceptives: Method Selection, Contraindications and Drug Interactions

Medical education review • Updated 10 November 2026. Not a substitute for individualized clinical assessment and local prescribing guidance.

Introduction

Hormonal contraception provides reversible pregnancy prevention through combined estrogen–progestin or progestin-only delivery systems. Appropriate choice depends on effectiveness, individual preferences, medical eligibility, menstrual goals, adherence, access and drug interactions. This review focuses on selecting and safely using methods; the companion article addresses pharmacology and mechanisms in detail [1–3].

Methods and effectiveness

  • Combined hormonal contraception (CHC): combined oral pills, transdermal patches and vaginal rings contain estrogen and progestin.
  • Progestin-only pills: formulations include norethindrone, norgestrel and drospirenone, with different missed-dose windows.
  • Progestin implants: etonogestrel implants provide long-acting highly effective contraception.
  • Injectables: depot medroxyprogesterone acetate (DMPA) provides months of protection per injection.
  • Levonorgestrel-releasing intrauterine devices: provide very effective contraception mainly by local effects on cervical mucus and endometrium. They do not contain estrogen.

Implants and intrauterine devices are among the most effective reversible methods with typical use because they do not depend on daily adherence [1,2].

Eligibility and contraindications

The CDC U.S. Medical Eligibility Criteria (MEC) distinguishes category 1 (no restriction), 2 (benefits generally outweigh risk), 3 (risks usually outweigh benefits), and 4 (unacceptable health risk). CHCs are generally contraindicated (MEC 4) in migraine with aura, current breast cancer, several high-risk thrombotic conditions and severe hypertension (systolic ≥160 mm Hg or diastolic ≥100 mm Hg). For smokers aged ≥35 years, CHC eligibility depends on cigarette exposure. Progestin-only methods may be suitable when estrogen is contraindicated, but are not risk free and have method-specific restrictions [1].

Postpartum, lactation and age

Combined estrogen-containing methods have important restrictions in the early postpartum period because venous thromboembolism risk is elevated; breastfeeding adds method- and timing-specific considerations. Progestin-only approaches are often suitable earlier postpartum, subject to individual assessment. Age alone is not a universal contraindication; clinical comorbidities determine eligibility [1].

Drug interactions

Enzyme-inducing anticonvulsants (such as carbamazepine, phenytoin and phenobarbital), rifampicin/rifabutin and some antiretrovirals may reduce effectiveness of certain hormonal methods. The impact depends on formulation; an intrauterine device is generally less affected. Lamotrigine exposure can decrease with estrogen-containing CHCs, potentially worsening seizure control; specialist coordination is important. Drospirenone-containing products warrant consideration of potassium-related drug interactions in indicated patients [1–3].

Adverse effects and counselling

Unscheduled bleeding, nausea, breast tenderness and headaches are common early effects and may diminish. Combined methods modestly increase venous thromboembolism risk; rare serious complications are more likely in those with underlying risk factors. DMPA may cause irregular bleeding, weight changes and reversible reductions in bone mineral density, with a possible delay to fertility return following the last injection. Neither hormonal contraceptives nor IUDs prevent sexually transmitted infections, so condoms and STI prevention remain relevant [1–3].

Practical decision-making

Avoid the misleading concept of ‘combined hormonal IUDs’: marketed levonorgestrel IUDs are progestin-only. Review patient priorities, timing, breastfeeding, pregnancy certainty, comorbidities, current medications and emergency contraception needs. Follow CDC selected practice recommendations for starting, switching, missed doses and backup contraception rather than assuming uniform missed-pill rules [2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Centers for Disease Control and Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1–126. Available from: https://www.cdc.gov/contraception/hcp/usmec/
  3. Centers for Disease Control and Prevention. U.S. Selected Practice Recommendations for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(3):1–77. Available from: https://www.cdc.gov/contraception/hcp/usspr/
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *